Covidien Builds Innovation Centers To Tailor Emerging Markets Strategy
This article was originally published in PharmAsia News
Covidien is optimistic about its emerging markets plans. The medical devices and supplies company is expanding its innovation and training network as an essential link to establish a long-term revenue model.
You may also be interested in...
Covidien acquired a privately held manufacturer of electrosurgical generators based in Ribeirao Preto, Brazil, and established a joint venture with a manufacturer of open stapler products based in Kiangsu Province in China, to access patients who can’t afford top-tier hospitals in those countries.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.